Pancreatitis
Conditions
Keywords
Extracorporeal Shock Wave lithotripsy(ESWL), Endoscopic Retrograde Cholangiopancreatography(ERCP), chronic pancreatitis, pain relief
Brief summary
The study wants to compare ESWL alone with ESWL and endoscopic drainage of the MPD for treatment of pain in chronic pancreatitis.
Detailed description
The combination mode of ESWL and ERCP is an established method of treatment of painful obstructive calcified chronic pancreatitis. However, the investigators notice that patients after ESWL alone in calcified CP is followed by spontaneous elimination of stone fragments and pain relief. Inui reported that 40% of 555 patients spontaneous eliminate stone fragments. Dumonceau found that combining systematic endoscopy with ESWL adds to the cost of patient care, without improving the outcome of the pancreatic pain. So the investigators design such a prospective and randomized controlled trial. People diagnosed with uncomplicated painful chronic pancreatitis and calcifications obstructing the MPD will be randomly assigned to the ESWL or endoscopy group according to a table of random numbers. ESWL will be performed in all patients using a electromagnetic lithotriptor. ESWL sessions will be repeated if necessary, until stone fragmentation is obtained. Patients in the endoscopy group will undergo endoscopy in 48 hours with possible stent insertion. In the ESWL group, if pain continues or aggravates, endoscopic drainage of the MPD will be carried out. Follow-up will consists of telephone interview1 after treatment and clinical examination every 6 months thereafter. Data collected will include clinical presentation, ESWL, endoscopic and surgical procedures, life quality. In addition, S-MRCP will be performed 6 months after treatment. Blood glucose, insulin, stool elastase will be taken each clinical examination.
Interventions
People in this group would be treated with ESWL only.
People in this group would be treated with ESWL followed be endoscopic drainage in 48 hours.
DRUGAnalgesics
Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.
Sponsors
Changhai Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* painful chronic pancreatitis(abdominal pain attack during the preceding 12 months); * at least 1 calcified stone greater than 5 mm in one of its axes in the cephalic or corporeal portion of the main pancreatic duct with upstream duct dilation; * no ERCP or ESWL carried out before admission
Exclusion criteria
* suspected to have malignant tumors; * history of pancreatic surgery or gastrojejunostomy (Billroth II); * pancreatic collection greater than 2 cm in diameter at magnetic resonance or CT scan; * age below 18 years; * pregnancy or lactation; * refuse to write informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline pain score as accessed by izbichi pain score at 12 month | 12 months | Whether pain is relieved depends on the change of Izbicki pain score at the baseline and 12 months after the procedure(ERCP alone or ERCP combined with ERCP). Izbicki pain score is composed of 4 parts, that is frequency of pain attacks(daily counts for 100, several times a week counts for 75, several times a month counts for 50, several times a year counts for 25 and several times a year counts for 0), VAS(subjective evaluation of pain by patients from no pain which is 0 points to imaginative maximum of pain which is 100 points), analgesic medication(morphine consumption is 100, buprenorphine is 80, pethidine is 20, tramaldol is 15, metamizole is 3 and acetylsalicylacid is 1) and time of disease-related inability to work(permanet is 100, ≤1 month is 50, ≤1 week is 25 and no inability to work during the last year is 0). Each part counts for 100 points in all. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| exocrine function of the pancreas through determination of fecal elastase as assessed by fecal elastase kit | 12 months | Pancreatic exocrine function insufficiency(PEI) is defined as fecal elastase \<200 μg/g. The result wii be divided into 4 conditions, that is exocrine function normal, PEI develop, PEI resolve, PEI persist. |
| clearance of pancreatic stones | 12 months | Clearance of pancreatic stone is regarded as complete when clearance rate is more than 90%, partial is regarded as 50% to 90%, the rest is unsuccessful. |
| decompression rate of the pancreatic duct as the change of pancreatic duct diameter assessed by S-MRCP | 12 months | — |
Other
| Measure | Time frame | Description |
|---|---|---|
| complication rate | 1 months | Complications involve pancreatitis, hemorrhage, perforation, infection and steinstrasse. |
| BMI in kg/m^2 | 12 months | — |
| endocrine function as assessed by the combination of fasting blood glucose, insulin, C peptide, glycosylated hemoglobin | 12 months | As mentioned earlier, the result of pancreatic endocrine function can also be divided into 4 parts similar to that of pancreatic exocrine function. |
| treatment-related cost from initial treatment to the end of the study(12 months) | 12 months | — |
| life quality as assessed by SF-36 questionnaire | 12 months | — |
Countries
China
Contacts
Primary ContactZhao-shen Li
Backup ContactZhuan Liao
Outcome results
None listed